Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CRSP stock, giving a Buy rating on November 6. Salim Syed’s rating is based on a combination of encouraging developments ...

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving ...

After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.